Li Lin

8501925, Aug 6, 2013

Jan 5, 2010

12/652395

Li Lin - Baltimore MD, US
John Pang - Baltimore MD, US
Wen Wei - Cockeysville MD, US
Edward G. Lakatta - Bel Air MD, US

The United States of America, as represented by the Secretary, Department of Health and Human Resources - Washington DC

C07H 21/04
C12Q 1/68

536 235, 435 61

Described herein are nucleic acid modules for cloning, expression and tagging of eukaryotic membrane proteins. The nucleic acid modules include a receptor for advanced glycation end products (RAGE) signal sequence, a nucleic acid sequence encoding a tag and a multiple cloning sequence (MCS). Any membrane protein of interest can be cloned into the MCS for expression in cells. The nucleic acid modules can encode any type of tag, such as an epitope tag or affinity tag. The nucleic acid modules disclosed herein can be used to express any type of membrane protein and are particularly suited to the expression and tagging of Type I and Type III membrane proteins.

20090099107, Apr 16, 2009

Aug 27, 2004

10/569884

Li Lin - Baltimore MD, US

The Johns Hopkins University - Baltimore MD

A61K 31/711
C07K 14/00
C12M 1/34
A61P 35/00
C12N 1/00

514 44, 530350, 435243, 4352871

A series of p105-based NF-κB super repressors, designated p-105(sr), have been designed. The p105(sr), no longer generates p50 and undergoes signal-induced degradation, effectively inhibiting all NF-κB activities. Additionally, p105(sr) significantly enhances tumor necrosis factor alpha (TNF-α)-mediated killing of MT1/2 skin papilloma cells when p50 homodimer activity is elevated. p105(sr) is an effective NF-κB super repressor with a broader range than other currently available IkBα super repressors. The novel repressor can be used in cells where a noncanical NF-κB activity is dominant or multiple NF-κB activities are activated.

20220305279, Sep 29, 2022

Jul 9, 2020

17/620032

- Washington DC, US
DAYUN YAN - Ashburn VA, US
XIAOLIANG YAO - Fairfax VA, US
Li LIN - Arlington VA, US
Vikas SONI - Washington DC, US
Jonathan SHERMAN - Potomac MD, US

A61N 2/00
A61K 31/495
A61P 35/00

A method and system of sensitization of cancerous cells in a volume is disclosed. A plasma tube including a pair of electrodes coupled to a power supply is provided. The plasma tube generates a plasma jet between the electrodes. A controller is coupled to a power supply to control a discharge voltage to the electrodes to generate the plasma jet and direct an electro-magnetic field at the volume having cancerous cells and normal cells for a sufficient time to sensitize the cancer cells. A treatment device applies a treatment such as TMZ to the sensitized cancer cells after the cancer cells are sensitized by the electro-magnetic field.

20190076537, Mar 14, 2019

Mar 16, 2017

16/076651

- Washington DC, US
Zhitong CHEN - Ashburn VA, US
Xiaoqian CHENG - Falls Church VA, US
Li LIN - Arlington VA, US

A61K 47/46
A61K 47/26
A61K 9/08
A61P 35/00
A61B 18/02
H05H 1/24

Solutions having a solvent and a cold atmospheric plasma dissolved in the solvent are described. Methods and systems of forming cold atmospheric plasma (CAP)-containing solutions are also described. A system for producing (CAP)-containing solutions includes a gas source; a plasma generating device having a hollow body fluidically coupled with the gas source, a closed proximal end and an open distal end, the hollow body receiving gas from the gas source, and at least one electrode in or about the hollow body and ionizing the gas to discharge a cold atmospheric plasma (CAP) from the open distal end; and a container for housing a fluid, the open distal end of the plasma generating device in fluid communication with an inner portion of the container. CAP-containing solutions can be used in treatment of cancer cells, infected tissue sterilization, microorganism inactivation, promotion of wound healing, skin regeneration, and blood coagulation, and teeth bleaching/whitening.